New drug combo may protect bones after spinal cord injury
NCT ID NCT05101018
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase 4 trial tests whether starting with romosozumab for 12 months and then switching to denosumab for another 12 months can better maintain bone density around the knee in people with recent spinal cord injury, compared to using denosumab alone. The study involves 40 adults aged 18-55 who have had a spinal cord injury for less than 6 months. Researchers will measure bone mineral density using X-ray scans to see which approach works best.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Romosozumab (Evenity) and Denosumab (Prolia)
- What this could lead to
- If successful, this could point toward a better treatment sequence to prevent severe bone loss and fractures after spinal cord injury.
- What could go wrong
- This is a small early-phase trial with only 40 participants, so results may not apply to everyone. Romosozumab carries heart risks, and the study excludes people with heart disease or stroke history.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 4
Runs after approval, following long-term safety and how well the treatment works in everyday use.
- Participants
-
About 40 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Nov 2021
- Expected to finish
-
Nov 2027
An estimate. End dates often move.
- Lead sponsor
-
A government agency
The lead sponsor is a US federal agency other than the NIH.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 55 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Traumatic motor-complete or incomplete SCI C4-L2 (AIS grade A-C); 2. Duration of SCI less than 6 months; 3. Males and females (premenopausal) between the ages of 18 and 55 years old; and a safe range of BMD right above the knee as determined by study staff review; Exclusion Criteria: 1. Active and/or history of coronary heart disease or stroke; 2. Bone cancer; 3. Long-bone fracture of the leg within the past year; 4. History of prior bone disease (for example, Paget's hyperparathyroidism, osteoporosis, etc.); 5. Postmenopausal women; 6. Men with known low functioning tests before SCI; 7. Drugs geared toward increasing BMD longer than a six month duration after SCI; 8. As determined by study staff review of my medication history of glucocorticoid administration longer than three months duration within the last year 9. Abnormalities of my endocrine glands such as hyperthyroidism, Cushing's disease or syndrome, etc.; 10. Severe underlying chronic disease (for example chronic obstructive pulmonary disease (COPD), end-stage heart disease, chronic renal failure); 11. Heterotopic ossification (HO) of the distal femur (the knee end of the thigh bone). HO is a condition where bone tissue forms outside of the skeleton. If HO is found in any other area than the distal femur it will not prevent my participation in the study.; 12. History of chronic alcohol abuse; 13. Diagnosis of hypercalcemia (high levels of calcium in the blood); 14. Pregnancy; 15. As determined by study staff review of my medications a bisphosphonate for heterotopic ossification (HO), or other medications to treat osteoporosis other than calcium and vitamin D; 16. Current diagnosis of cancer or history of cancer; 17. As determined by study staff review of my medications, prescribed moderate or high dose corticosteroids (\>40 mg/d prednisone or an equivalent dose of other corticosteroid medication) for longer than one week, not including drug administered to preserve neurological function at the time of acute SCI; and 18. Life expectancy less than 5 years.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Osteoporosis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
James J. Peters VA Medical Center
The Bronx, New York, 10468, United States
-
Kessler Institute for Rehabilitation
West Orange, New Jersey, 07052, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Pregnancy hormone hCG may hold clues to bone and gland health
- Serotonin precursor probed for spinal cord injury effects
- Breathing brief Low-Oxygen bursts may boost sleep apnea treatment
- Pure oxygen tested as a switch for dormant nerves after spinal cord injury
- Spinal stimulation tested to help kids with spinal cord injuries sit taller
- Zapping the spine: a new hope for kids with paralysis?